Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2022 08:30 ET | Source: Agenus Inc.

Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference

LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo...
November 14, 2022 08:30 ET | Source: Agenus Inc.

Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

Overall response rates ranged from 22% in microsatellite stable colorectal cancer (MSS-CRC) to 60% in PD-(L)1 refractory non-small cell lung cancer (NSCLC)Initiated Phase 2 ACTIVATE trials of...
November 08, 2022 08:00 ET | Source: Agenus Inc.

Agenus Provides Corporate Update and Third Quarter 2022 Financial Report

Company to present expanded data from Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) at plenary session of the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingInitiated Phase 2...
October 25, 2022 08:30 ET | Source: Agenus Inc.

Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report

Conference Call on Tuesday, November 8, 2022, at 8:30 a.m. ETCompany to host “The Road Taken” R&D Event in Boston on November 12 from 2p.m. – 5p.m. ET to discuss with oncology experts clinical...
October 13, 2022 08:32 ET | Source: Agenus Inc.

GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial

Data show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with consistent high vaccine efficacy observed in severe disease...
October 12, 2022 08:00 ET | Source: Agenus Inc.

VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients

Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022Study expected to assess VBI-1901 with concurrent balstilimab (anti-PD-1)...
October 05, 2022 08:30 ET | Source: Agenus Inc.

Agenus to Host “The Road Taken” R&D Event on November 12, 2022

LEXINGTON, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers...
October 05, 2022 08:00 ET | Source: Agenus Inc.

Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Clinical data in nine cancer indications from trial with 264 patients accruedPlenary discussion relating to expansion cohorts represent heavily pretreated patientsAdditional SITC presentations cover...
September 12, 2022 08:30 ET | Source: Agenus Inc.

Agenus Makes Senior Regulatory and Clinical Appointments

Patricia Carlos named Chief Regulatory, Quality, and Safety OfficerTodd Yancey, MD named Senior Global Clinical Development, Medical Affairs and Commercial Advisor LEXINGTON, Mass., Sept. 12, 2022 ...
September 12, 2022 08:30 ET | Source: Agenus Inc.

Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma

Phase 2 ACTIVATE trials to advance globally in metastatic patients who have progressed on available therapiesBotensilimab, alone and in combination with balstilimab (PD-1), has demonstrated robust...